TADalafil in early-stage Parkinson’s Disease (TAD-PD)
Key facts
- Where
- Amsterdam, HollandiaSee the site
- Phase
- 2. fázis
Where in Hollandia
- Amsterdam UMC Research B.V.Amsterdam, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amsterdam UMC Stichting
- Trial code
- EU 2025-521819-39-00
- Record updated
- 2026. január 5.
- Original description
To assess whether daily tadalafil improves motor symptoms in Parkinson-drug naïve patients with early-stage Parkinson’s disease over a two-week follow-up periodRead full original descriptionShow less
Prospective, Open-Label, Single-Center Pilot Study on the Efficacy of Daily Tadalafil in Early-Stage Parkinson’s Disease
To assess whether daily tadalafil improves motor symptoms in Parkinson-drug naïve patients with early-stage Parkinson’s disease over a two-week follow-up period
Inclusion: Diagnosis of early-stage Parkinson’s disease, with no limitations in daily functioning that would necessitate symptomatic treatment; No prior medication for Parkinson’s disease; Normal blood pressure (between >90/60 mm Hg and <120/80 mm Hg); Age older than 18 years; Informed consent and comply with the study protocol; Understand the Dutch language.
Exclusion: Currently taking PDE-inhibitors for erectile dysfunction; Concurrent nitrate, nitric oxide donors, guanylate cyclase, nicorandil, theophylline alpha-blocker, cytochrome P-450 3A4 (CYP3A4) inhibitor/inducer, or prostacyclin analog use; Significant alcohol or drug abuse; (unstable) Cardiovascular and cerebrovascular disease; Unilateral blindness, hereditary retinal disorders, or increased risk of blindness; Unilateral deafness or history of severe hearing loss dependent upon hearing aid(s); Mild cognitive impairment (MCI) or dementia; Suspicion of or a known history of renal (eGFR level < 80 ml/min) or hepatic insufficiency; Multisystem atrophy (MSA); Abnormal electrocardiogram (ECG); Orthostatic hypotension: a decrease in systolic blood pressure ≥ 20 mmHg, or a decrease in diastolic blood pressure ≥ 10 mmHg; Immunocompromised; Pregnancy and breastfeeding; Legally incompetent adults; Clinically significant penile deformity.